However, the last few decades have brought significant improvement to the treatment of hemophilia A. The development of recombinant FVIII (rFVIII) products not only resolved the issue of relying on human plasma source availability but also facilitated the development of new products. The gene discussed is F8; the disease is hemophilia A.